Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
Go back to Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)| Gilead Sciences (NASDAQ: GILD) | Delayed: 124.87 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $124.87 | 52 Week High | $108.63 | |||
| Open | $124.87 | 52 Week Low | $71.39 | |||
| Day High | $124.87 | P/E | 68.99 | |||
| Day Low | $124.87 | EPS | $1.81 | |||
| Volume | 9,531 | |||||
